Is Serum Caveolin-1 a Useful Biomarker for Progression in Patients with Colorectal Cancer?

Erdemli H. K. , Kocabas R., ŞALIŞ O., Sen F., Akyol S., Eskin F., ...More

CLINICAL LABORATORY, vol.62, no.3, pp.401-408, 2016 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 62 Issue: 3
  • Publication Date: 2016
  • Doi Number: 10.7754/clin.lab.2015.150719
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.401-408


Background: Colorectal cancer (CRC) is the third most common cause of cancer diagnosed in males and the second in females. Survival is strongly related to stage at diagnosis. There is an urgent need to find a noninvasive biomarker that can be commonly applied for screening diagnosis, early detection of recurrence, and monitoring of metastatic CRC. Protein caveolin-1 (CAV-1) has been known to be expressed abnormally in colon cancer and appears to contribute to aberrant signaling and protein trafficking. There are controversial results regarding the role of CAV-1 in cancer. We hypothesized that levels of CAV-1 in serum of patients with CRC might be important to estimate the progression of the disease. Therefore, the purpose of this study is to investigate whether serum CAV-1 might be used as a factor determining progression of CRC.